Your browser doesn't support javascript.
loading
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Mateos, Maria-Victoria; Dimopoulos, Meletios A; Cavo, Michele; Suzuki, Kenshi; Knop, Stefan; Doyen, Chantal; Lucio, Paulo; Nagy, Zsolt; Pour, Ludek; Grosicki, Sebastian; Crepaldi, Andre; Liberati, Anna Marina; Campbell, Philip; Yoon, Sung-Soo; Iosava, Genadi; Fujisaki, Tomoaki; Garg, Mamta; Iida, Shinsuke; Bladé, Joan; Ukropec, Jon; Pei, Huiling; Van Rampelbergh, Rian; Kudva, Anupa; Qi, Ming; San-Miguel, Jesus.
Afiliação
  • Mateos MV; University Hospital of Salamanca/IBSAL, Cancer Research Center IBMCC (USAL-CSIC), Salamanca, Spain. Electronic address: mvmateos@usal.es.
  • Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece.
  • Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
  • Suzuki K; Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan.
  • Knop S; Würzburg University Medical Center, Würzburg, Germany.
  • Doyen C; Université Catholique de Louvain, Yvoir, Belgium.
  • Lucio P; Champalimaud Centre for the Unknown, Lisbon, Portugal.
  • Nagy Z; Semmelweis Egyetem, Budapest, Hungary.
  • Pour L; University Hospital Brno, Brno-Bohunice-Brno-Starý Lískovec, Czech Republic.
  • Grosicki S; Department of Hematology and Cancer Prevention in Chorzów, Faculty of Health Sciences in Bytom, Medical University of Silesia, Katowice, Poland.
  • Crepaldi A; Clinica de Tratamento E, Cuiaba, Brazil.
  • Liberati AM; Università degli Studi di Perugia Azienda Ospedaliera "Santa Maria," Terni, Italy.
  • Campbell P; Andrew Love Cancer Centre, University Hospital Geelong, Geelong, VIC, Australia.
  • Yoon SS; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Iosava G; Medinvest-Institute of Hematology, Tbilisi, Georgia.
  • Fujisaki T; Matsuyama Red Cross Hospital, Matsuyama, Japan.
  • Garg M; Leicester Royal Infirmary - Haematology, Leicester, United Kingdom.
  • Iida S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku Nagoya, Japan.
  • Bladé J; Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
  • Ukropec J; Janssen Global Medical Affairs, Horsham, PA.
  • Pei H; Janssen Research & Development, LLC, Titusville, NJ.
  • Van Rampelbergh R; Janssen Research & Development, Beerse, Belgium.
  • Kudva A; Janssen Research & Development, LLC, Raritan, NJ.
  • Qi M; Janssen Research & Development, LLC, Spring House, PA.
  • San-Miguel J; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Navarra, Spain.
Clin Lymphoma Myeloma Leuk ; 21(11): 785-798, 2021 11.
Article em En | MEDLINE | ID: mdl-34344638
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Bortezomib / Melfalan / Anticorpos Monoclonais / Mieloma Múltiplo Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Bortezomib / Melfalan / Anticorpos Monoclonais / Mieloma Múltiplo Idioma: En Ano de publicação: 2021 Tipo de documento: Article